Arcturus Therapeutics Holdings Inc.

NasdaqGM:ARCT Rapporto sulle azioni

Cap. di mercato: US$438.0m

Arcturus Therapeutics Holdings Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Arcturus Therapeutics Holdings non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-1.5%

Rendimento del riacquisto

Rendimento totale per gli azionisti-1.5%
Rendimento futuro dei dividendi0%
Crescita dei dividendin/a
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Rapporto di remunerazionen/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14

Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified

Oct 04
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified

Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

Sep 06
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 09

Arcturus: A Hidden Gem In The Biotech Sector

Jun 08

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

May 29
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis

Apr 23

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Apr 09
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Feb 06
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Arcturus: H1 2024 Rare Disease Drug Data On Deck

Jan 31

Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Jan 11
Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Dec 14
Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Sep 14
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Aug 08
Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Jul 19
Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

May 18
Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

May 02
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Dec 28
Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 23
Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine

Aug 31

Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Aug 15
Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks

Aug 10

Arcturus: Potential Based On Rare Disease Therapy ARCT-810

Jun 07

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di ARCT siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di ARCT siano aumentati.


Rendimento dei dividendi rispetto al mercato

Arcturus Therapeutics Holdings Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di ARCT rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (ARCT)n/a
Fondo del 25% del mercato (US)1.4%
Top 25% del mercato (US)4.3%
Media del settore (Biotechs)2.3%
Analista previsionale (ARCT) (fino a 3 anni)0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di ARCT rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di ARCT rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.


Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di ARCT per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.


Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché ARCT non ha segnalato alcun pagamento.


Scoprire le società che pagano dividendi forti